Get to know our clinical trials
Phase II clinical trial to evaluate the efficacy and safety of ZN-c3 in patients with high-grade serous ovarian, fallopian tube or primary peritoneal ovarian cancer
THE MAIN OBJECTIVE OF THIS STUDY IS: PART 1B: TO DETERMINE THE SAFETY AND TOLERABILITY OF ZN-C3 IN PROC SUBJECTS PART 2: TO INVESTIGATE THE ANTITUMOR ACTIVITY OF ZN-C3 IN PROC SUBJECTS
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZN-C3 IN PATIENTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL OVARIAN CANCER
- Code EudraCT: 2022-502983-19-00
- Protocol number: ZN-c3-005
- Promoter: Zentalis Pharmaceuticals, Inc.
- Molecule/Drug: ZN-c3
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.